Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

Background Ferric carboxymaltose therapy reduces symptoms and improves quality of life in
patients who have heart failure with a reduced ejection fraction and iron deficiency …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Iron deficiency is one of the leading contributors to the global burden of disease, and
particularly affects children, premenopausal women, and people in low-income and middle …

Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of patients
with coronary artery disease, and an even higher proportion of those with heart failure (HF) …

Anemia is a common complication in chronic kidney disease (CKD), and is associated with a
reduced quality of life, and an increased morbidity and mortality. The mechanisms involved …

The 2021 Update to the 2017 American College of Cardiology (ACC) Expert Consensus
Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues …

Rationale: Maintaining iron homeostasis is essential for proper cardiac function. Both iron
deficiency and iron overload are associated with cardiomyopathy and heart failure via …